Capital Flow Monitor · Sponsors · CIK 2132995
Octagon Biotech Opportunities Fund II LP
654 MADISON AVENUE, FL. 21, NEW YORK, NY, 10065 · 212-369-2829
Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. DELAWARE true 2026
Fit score
—
Offering
$175.0M
Sold
$17.8M
% sold
10.2%
Investors
5
Min investment
$5.0M
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | D ·current | 506(b) | $175.0M | $17.8M | 10.2% | 5 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
n/a Octagon Investments GP, LLC — Director / Promoter, New York, NY
2 other raises
- Octagon Biotech Opportunities Offshore Fund II LP $53.9M of $175.0M · 30.8%
- Octagon Investments Fund LP $380.1M of —
-
n/a Octagon Capital Advisors LP — Promoter, New York, NY
3 other raises
- Octagon Biotech Opportunities Offshore Fund II LP $53.9M of $175.0M · 30.8%
- Octagon Investments Offshore Fund Ltd. $709.3M of —
- Octagon Investments Fund LP $380.1M of —
-
Dr. Ting Jia — Executive Officer, New York, NY
1 other raise
- Octagon Biotech Opportunities Offshore Fund II LP $53.9M of $175.0M · 30.8%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.